The burgeoning landscape of novel treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable https://tbookmark.com/story20580684/retatrutide-vs-tirzepatide-a-comparative-analysis